The Filing Desk

CRISPR Therapeutics vs Ocugen

CRISPR Therapeutics CRSP · Ocugen OCGN · Biotechnology

Ocugen reported revenue of $4 million in fiscal 2025, 1.3 times CRISPR Therapeutics' $4 million in fiscal 2025. CRISPR Therapeutics' revenue fell 90.6% in its latest year, and Ocugen's grew 8.8%. CRISPR Therapeutics had an operating margin of -18933.7%, against -1425.7% at Ocugen. Free cash flow was −$346 million at CRISPR Therapeutics and −$57 million at Ocugen.

Side by side

CRISPR TherapeuticsOcugen
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$4M$4M
Revenue growth−90.6%8.8%
Revenue growth a year, last 5 years38.0%—
Gross margin——
Operating margin−18,933.7%−1,425.7%
Net margin−16,569.8%−1,537.4%
Free cash flow−$346M−$57M
Free cash flow margin−9,855.5%−1,295.0%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count6.6%—
Last close$38.93$0.73
P/E at the last close——
Insider trades, last 12 monthssold $14.5 millionbought $25,830, sold $589,110
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
CRISPR TherapeuticsOcugen
Operating margin
Percent of revenue
CRISPR TherapeuticsOcugen
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CRISPR TherapeuticsOcugen

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the CRISPR Therapeutics and Ocugen pages.